Application of liposomes in antigen presentation and cytokine delivery

Journal of Liposome Research

Volumn 6, Issue 2, 1996, Pages 305-323

  Dong, Penny ^a   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; LIPOSOME; TRINITROPHENYL;

ANIMAL CELL; ANTIGEN PRESENTATION; B LYMPHOCYTE ACTIVATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; IMMUNE RESPONSE; IMMUNOPOTENTIATION; LIPID MEMBRANE; MEMBRANE FLUIDITY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0029890189     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.3109/08982109609031119     Document Type: Review

References (46)

1. Allison, A.C., Gregoriadis, G. 1974. Liposomes as immunological adjuvants. Nature 252:252.
2. Khan, M.Z., Opdebeeck, J.P., Tucker, I.G. 1994. Immunopotentiation and delivery systems for antigens for single-step immunization: recent trends and progress. Pharm. Res. 11:2.
3. Kinsky, S.C. 1980. Factors affecting liposomal model membrane immunogenicity. In Liposomes and Immunology (Eds. Tom, B., Six, H.R.) Elsevier/North Holland, New York, pp.79-90.
4. Six, H., Anderson, C., Kasel, J. 1988. Further studies of liposomes as carriers of purified protein vaccines. In Liposomes as Drug Carriers: recent trends and progress (Ed. Gregoriadis, G.) John Wiley & Sons, New York.
5. Yasuda, T., Darcey, G.F., Kinsky, S.C. 1977. Immunogenicity of liposomal model membranes in mice: dependence on phospholipid composition. Proc. Natl. Acad. Sci. USA 74:1234.
6. Ohyama, N., Hamano, T., Hamakawa, N., Inagaki, K., Nakanishi, M. 1991. Membrane fluidity and lipid hapten structure of liposomes affect calcium signals in antigen-specific B cells. Biochemistry 30:11154.
7. Grover, A., Sundharadas, G. 1986. Effect of liposomes on lymphocyte induction of proliferation of B lymphocytes and potentiation of the cytotoxic response of T lymphocytes to alloantigens. Eur. J. Immunol. 16:665.
8. Garnier, F., Forquet, F., Bertolino, P., Grelier, D. 1991. Enhancement of in vivo and in vitro T cell response against measles virus haemagglutinin after its incorporation into liposomes: effect of the phospholipid composition. Vaccine 9:340.
9. Unanue, E.R., Cerottini, J.C. 1989. Antigen presentation. FASEB J. 3:2496.
10. Townsend, A., Bodmer, H. 1989. Antigen recognition by class I-restricted T lymphocytes. Ann. Rev. Immunol. 7:601.
11. Fisher, S., Riley, W.B., Shorey, C.D. 1968. Studies on the mechanism of increased splenic particle uptake in mice after the injection of some finely divided agents. J. Pathol. Bacteriol. 96:463.
12. Sjoholm, I., Edman, P. 1979. Acrylic microspheres in vivo. I. Distribution and elimination of polyacrylamide microparticles after intravenous and intraperitoneal injection in mouse and rat. J. Pharmacol. Exp. Ther. 211:656.
13. Fidler, I.J. 1985. Macrophages and metastasis: a biological approach to cancer therapy. Cancer Res. 45:4714.
14. Ho, R.J.Y., Burke, R.L., Merigan, T.C. 1994. Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD. Vaccine 12:235.
15. Bryson, Y.J., Dillon, M., Lovett, M., Acuna, G., Taylor, S., Cherry, J.D., Johnson, B.L., Wismeier, E., Growdon, W., Greagh-Kirk, T., Keeney, R. 1983. Treatment of first episodes of genital herpes simplex with oral acyclovir. N. Engl. J. Med. 308:916.
16. Mertz, G.J., Critchlow, C.W., Benedetti, J., Reichman, R.C., Dolin, R., Connor, J., Redfield, D.C., Savoia, M.C., Richman, D.D., Tyrrell, D.L., Miedzinski, L., Protnoy, J., Kenney, R.E., Corey, L. 1984. Double-blind placebo-controlled trial of oral acyclovir in first episode genital herpes simplex virus infection. JAMA 252:1147.
17. Douglas, J.M., Critchlow, C., Benedetti, J., Mertz, G.J., Connor, J.D., Hintz, M.A., Fahnlander, A., Remington, M., Winter, C., Corey, L.A. 1984. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. 310:1551.
18. Straus, S.W., Corey, L., Burke, R.L., Savarese, B., Barnum, G., Grause, P.R., Kost, R.G., Meier, J.L., Sekulovich, R., Adair, S.F. 1994. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460.
19. Stanberry, L.R., Kern, E.R., Richards, J.T., Overall, J.C. Jr. 1985. Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology 24:226.
20. Ho, R.J.Y., Burke, R.L., Merigan, T.C. 1989. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. J. Virol. 63:2951.
21. Dong, P., Brunn, C, Ho, R.J.Y. 1994. Cytokines as vaccine adjuvants: current status and potential applications. In Vaccine design: the subunit approach. (Eds. Powell, M., Newman, M.) Plenum Publishing, New York. In press.
22. Smith, K.A. 1992. Interleukin-2. Curr. Opin. Immunol. 4:271.
23. Costello, R., Imbert, J., Olive, D. 1993. Interleukin-7, a major T-lymphocyte cytokine. Eur. Cytokine Netw. 4:253.
24. Henney, C.S. 1989. Interleukin 7: effects on early events in lymphopoiesis. Immunol. Today 10:170.
25. Bui, T., Faltynek, C.R., Ho, R.J.Y. 1994. Biological response of recombinant interleukin-7 on herpes simplex virus infection in guinea-pigs. Vaccine 12:646.
26. Meuer, S.C., Dumann, H., Meyer-zum-Buschenfelde, K.H., Kohler, H. 1989. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15.
27. Rose, R.M., Rey-Martinez, J., Croteau, C., Silverstri, R.C., Haley, K., Depamphilis, J., Siber, G.R. 1992. Failure of recombinant interleukin-2 to augment the primary humoral response to a recombinant hepatitis B vaccine in healthy adults. J. Infect. Dis. 165:775.
28. Jungers, P., Devillier, P., Salomon, H., Cerisier, J.E., Courouce, A.M. 1994. Randomized placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 344:856.
29. Schijns, V.E., Claassen, I.J., Vermeulen, A.A., Horzinek, M.E., Osterhaus, A.D. 1994. Modulation of antiviral immune responses by exogenous cytokines: effects of tumor necrosis factor-alpha, interleukin-1 alpha, interleukin-2 and interferon-gamma on the immunogenicity of an inactivated rabies vaccine. J. Gen. Virol. 75:55.
30. Villacres-Eriksson, M., Bergstrom-Mollaoglu, M., Kaberg, H., Morein, B. 1992. Involvement of interleukin-2 and interferon-gamma in the immune response induced by influenza virus. Scand. J. Immunol. 36:421.
31. Weinberg, A., Merigan, T.C. 1988. Recombinant interleukin 2 as adjuvant for vaccine-induced protection: immunization of guinea pigs with herpes simplex virus subunit vaccines. J. Immunol. 140:294.
32. Hazama, M., Mayumi-Aono, A., Asakawa, N., Kuroda, S., Hinuma, S., Fujisawa, Y. 1993. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2. Vaccine 11:629.
33. Ruby, J., Brinkman, C., Jones, S., Ramshaw, I. 1990. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Immunol. Cell. Biol. 68:113.
34. Ho, R.J.Y., Burke, R.L., Merigan, T.C. 1992. Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs. Vaccine 10:209.
35. Bui, T., Faltynek, C., Ho, R.J.Y. 1994. Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: effects on blood lymphocyte population in guinea pigs. Pharm. Res. 11:633.
36. Bui, T., Dykers, T., Hu, S.-L., Faltynek, C.R., Ho, R.J.Y. 1994. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. J. Acquir. Immune Defic. Syndr. 7:799.
37. Antoni, G., Presentini, R., Perin, F., Nencioni, L., Villa, L., Censini, S., Ghiara, P., Volpini, G., Bossu, P., Tagliabue, A., Boraschi, D. 1989. Interleukin-1 and its synthetic peptides as adjuvants for poorly immunogenic vaccines. Adv. Exp. Med. Biol. 251:153.
38. Heber-Katz, E., Dietzschold, B. 1986. Immune response to synthetic herpes simplex virus peptides: the feasibility of a synthetic vaccine. Curr. Top. Microbiol. Immunol. 130:51.
39. Brynestad, K., Babbit, B., Huang, L., Rouse, B.T. 1990. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J. Virol. 64:680.
40. Tartaglia, J., Pincus, S., Paoletti, E. 1990. Poxvirus-based vectors as vaccine candidates. Crit. Rev. Immunol. 10:13.
41. Andrew, M.E., Boyle, D.B., Coupar, B.E., Reddy, D., Bellamy, A.R., Both G.W. 1992. Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea. Vaccine 10:185.
42. Sedegah, M., Chiang, C.H., Weiss, W.R., Mellouk, S., Cochran, M.C., Houghten, R.A., Beaudoin, R.L., Smith, D., Hoffman, S.L. 1992. Recombinant pseudorabies virus carrying a plasmodium gene: herpes virus as a new live viral vector for inducing T- and B-cell immunity. Vaccine 10:578.
43. Hu, S.L., Abrams, K., Barber, G.N., Moran, P., Zarling, J.M., Langlois, A.J., Kuller, L., Morton, W.R., Benveniste, R.E. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456.
44. Hu, S.L., Klaniecki, J., Dykers, T., Sridhar, P., Travis, B.M. 1991. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. AIDS-Res. Hum. Retroviruses. 7:615.
45. Muranishi, S. 1991. Drug targeting towards the lymphatics. Adv. Drug Res. 21:1.
46. Supersaxo, A. 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7:167.